Actively Recruiting

Phase Not Applicable
Age: 17Years - 65Years
All Genders
NCT05791487

Combination of Diet and Oral Budesonide for Ulcerative Colitis

Led by Wolfson Medical Center · Updated on 2024-05-23

90

Participants Needed

6

Research Sites

143 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The ReDUCE Trial is a multinational single-blinded randomized controlled trial in mild to moderate flare of Ulcerative colitis (UC) disease patients. The purpose of the study is to validate the clinical efficacy of the UCED (Ulcerative colitis Exclusion Diet) with partial enteral nutrition (PEN) using a novel formula. The investigators anticipate that adding a novel specifically designed dietary intervention in addition to drug will lead to superior remission and mucosal healing via changes in the microbiome.

CONDITIONS

Official Title

Combination of Diet and Oral Budesonide for Ulcerative Colitis

Who Can Participate

Age: 17Years - 65Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Signed informed consent
  • Diagnosed Ulcerative Colitis with mild to moderate active disease (SCCAI 5 to 10)
  • Age between 17 and 65 years inclusive
  • Disease extent E1 to E3 by Montreal classification
  • Active colitis in rectum or sigmoid colon confirmed by sigmoidoscopy
  • Stable use of oral 5ASA for at least 8 weeks, or thiopurines, vedolizumab, ustekinumab, or tofacitinib for at least 12 weeks
Not Eligible

You will not qualify if you...

  • Severe colitis (SCCAI greater than 10) or hospitalization for acute severe colitis within past 6 months
  • Steroid use within previous 3 months
  • Current anti-TNF treatment or previous failure/loss of response to anti-TNF
  • Vegan diet
  • Pregnancy
  • Unable to use budesonide due to severe adverse events
  • Extraintestinal manifestations like arthritis, spondyloarthropathy, or uveitis
  • Baseline hypoalbuminemia
  • Fever over 38 degrees Celsius
  • Evidence of Clostridioides difficile infection
  • Renal failure
  • Hepatitis or Primary Sclerosing Cholangitis (PSC)
  • Active malignancy excluding skin basal cell carcinoma

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 6 locations

1

Emek Medical Center

Afula, Israel, 1834111

Not Yet Recruiting

2

Wolfson Medical Center

Holon, Israel, 58100

Actively Recruiting

3

Tel Aviv Sourasky Medical Center

Tel Aviv, Israel, 6423906

Actively Recruiting

4

FONDAZIONE GEMELLI HOSPITAL Catholic University of the Sacred Hearth

Roma, Italy, 00168

Not Yet Recruiting

5

Radboud University Medical Center (Radboudumc)

Nijmegen, Netherlands

Not Yet Recruiting

6

Kantonsspital St. Gallen

Sankt Gallen, Switzerland

Actively Recruiting

Loading map...

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here